Toxic epidermal necrolysis associated with phenytoin in a 6-year-old child: a case report

Saman Beg; Jasim Qureshi; Jaigham Abbas; Khatibur Rahman

doi:10.18203/2349-3291.ijcp20242351

Authors

Saman Beg Department of Pediatrics, Career Institute of Medical Sciences and Hospital, Lucknow, Uttar Pradesh, India
Jasim Qureshi Department of Pediatrics, Career Institute of Medical Sciences and Hospital, Lucknow, Uttar Pradesh, India
Jaigham Abbas Department of Pediatrics, Career Institute of Medical Sciences and Hospital, Lucknow, Uttar Pradesh, India
Khatibur Rahman Department of Pediatrics, Career Institute of Medical Sciences and Hospital, Lucknow, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2349-3291.ijcp20242351

Keywords:

TEN, Phenytoin, Cyclosporine

Abstract

Toxic epidermal necrolysis (TEN) is a severe mucocutaneous syndrome often triggered by adverse drug reactions, characterized by extensive skin detachment. We present a rare case of a 6-year-old boy developing TEN associated with phenytoin use for post-bacterial meningitis seizures. The patient initially presented with fever, epigastric pain, oral ulcers, and skin rashes, later progressing to extensive skin peeling. Phenytoin was promptly discontinued. The SCORTEN score indicated a mortality rate of 35.3%. Informed consent was taken by parents. The patient received supportive care, including IV fluids, antibiotics, and topical treatments. The patient exhibited a positive response to early initiation of systemic steroids (Dexamethasone) and cyclosporine, leading to a successful recovery within 15 days. This case underscores the importance of recognizing and managing drug induced TEN promptly, especially in pediatric populations, and highlights potential immunopathologic pathways and genetic predispositions to the condition.

Metrics

Metrics Loading ...

References

Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol. 1993;129(1):92-6.

Chang WC, Abe R, Anderson P, Anderson W, Ardern-Jones MR, Beachkofsky TM, et al. SJS/TEN 2019: From science to translation. J Dermatolog Sci. 2020;98(1):2-12.

Struck MF, Hilbert P, Mockenhaupt M, Reichelt B, Steen M. Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. Intensive Cre Med. 2009;36(1):22-32.

Alerhand S, Cassella C, Koyfman A. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Pediatric Population. Pediatr Emergency Care. 2016;32(7):472-6.

Nagy N, McGrath JA. Blistering skin diseases: a bridge between dermatopathology and molecular biology. Histopathology. 2010;56(1):91-9.

Abe R, Shimizu T, Akihiko Shibaki, Nakamura H, Watanabe H, Shimizu H. Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome Are Induced by Soluble Fas Ligand. Am J Pathol. 2003;162(5):1515-20.

Posadas SJ, Padial A, Torres MJ, Mayorga C, Leyva L, Sanchez E, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Aller Clin Immunol. 2002;109(1):155-61.

Paul C, Wolkenstein P, Adle H, Wechsler J, Henri-Jean Garchon, Revuz J, et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol. 1996;134(4):710-4.

Nassif A, Moslehi H, Le Gouvello S, Bagot M, Lyonnet L, Michel L, et al. Evaluation of the Potential Role of Cytokines in Toxic Epidermal Necrolysis. J Investigat Dermatol. 2004;123(5):850-5.

Chung WH, Hung SI, Yang JY, Su SC, Huang SP, Wei CY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nature Med. 2008;14(12):1343-50.

Kulkarni S, Dattatri AN. Phenytoin induced Stevens-Johnson syndrome: a case report. Int J Basic Clin Pharmacol. 2018;7(3):573.

Fakoya AOJ, Omenyi P, Anthony P, Anthony F, Etti P, Otohinoyi DA, et al. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis; Extensive Review of Reports of Drug-Induced Etiologies, and Possible Therapeutic Modalities. Open Access Macedonian J Med Sci. 2018;6(4):730-8.

Hu FY, Wu XT, An DM, Yan B, Stefan H, Zhou D. Phenytoin-induced Stevens–Johnson syndrome with negative HLA-B*1502 allele in mainland China: Two cases. Seizure. 2011;20(5):431-2.

Wolkenstein PE, Roujeau JC, Revuz J. Drug-Induced Toxic Epidermal Necrolysis. Clin Dermatol. 1998;16(3):399-408.

Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P. SCORTEN: A Severity-Of-Illness Score for Toxic Epidermal Necrolysis. J Investigative Dermatol. 2000;115(2):149-53.

Saha K, Gupta AK. Toxic epidermal necrolysis: Current concepts in pathogenesis and treatment. Indian J Dermatol Venereol Leprol. 2000;66(1):10-7.

Lin CC, Chen CB, Wang CW, Hung SI, Chung WH. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. Expert Rev Clin Immunol. 2020;16(4):373-87.

Coulombe J, Eugénie B, Duhamel A, Rault P, Buteau C, Jacques J, et al. Pediatric SJS/TEN Subdued by a Combination of Dexamethasone, Cyclosporine, and Etanercept. J Cutaneous Med Surg. 2019;23(5):54750.